EP1446416A4 - Tumorspezifische monoklonale antikörper - Google Patents

Tumorspezifische monoklonale antikörper

Info

Publication number
EP1446416A4
EP1446416A4 EP02803674A EP02803674A EP1446416A4 EP 1446416 A4 EP1446416 A4 EP 1446416A4 EP 02803674 A EP02803674 A EP 02803674A EP 02803674 A EP02803674 A EP 02803674A EP 1446416 A4 EP1446416 A4 EP 1446416A4
Authority
EP
European Patent Office
Prior art keywords
monoclonal antibodies
specific monoclonal
tumor specific
tumor
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02803674A
Other languages
English (en)
French (fr)
Other versions
EP1446416A1 (de
Inventor
Jeffry D Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Molecular Evolution Inc
Original Assignee
Applied Molecular Evolution Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Evolution Inc filed Critical Applied Molecular Evolution Inc
Publication of EP1446416A1 publication Critical patent/EP1446416A1/de
Publication of EP1446416A4 publication Critical patent/EP1446416A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP02803674A 2001-11-19 2002-11-19 Tumorspezifische monoklonale antikörper Withdrawn EP1446416A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98990101A 2001-11-19 2001-11-19
US989901 2001-11-19
PCT/US2002/037134 WO2003044036A1 (en) 2001-11-19 2002-11-19 Tumor specific monoclonal antibodies

Publications (2)

Publication Number Publication Date
EP1446416A1 EP1446416A1 (de) 2004-08-18
EP1446416A4 true EP1446416A4 (de) 2005-11-30

Family

ID=25535569

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02803674A Withdrawn EP1446416A4 (de) 2001-11-19 2002-11-19 Tumorspezifische monoklonale antikörper

Country Status (8)

Country Link
EP (1) EP1446416A4 (de)
JP (1) JP2005517388A (de)
CN (1) CN1615315A (de)
AU (1) AU2002365978A1 (de)
BR (1) BR0214288A (de)
CA (1) CA2467020A1 (de)
MX (1) MXPA04004658A (de)
WO (1) WO2003044036A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679516B (zh) * 2007-05-31 2013-11-13 默沙东公司 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白
CA2836468C (en) 2011-05-17 2021-05-04 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
KR20210011919A (ko) 2018-04-17 2021-02-02 셀덱스 쎄라퓨틱스, 인크. 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032635A2 (en) * 1998-12-02 2000-06-08 Ixsys, Incorporated Tumor specific human monoclonal antibodies and methods of use
WO2000063699A1 (en) * 1999-04-20 2000-10-26 Philogen S.R.L. A tenascin-c isoform as a marker for neoplasias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
CA2229043C (en) * 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
ATE403001T1 (de) * 1996-05-22 2008-08-15 Viventia Biotech Inc Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
US6303323B1 (en) * 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032635A2 (en) * 1998-12-02 2000-06-08 Ixsys, Incorporated Tumor specific human monoclonal antibodies and methods of use
WO2000063699A1 (en) * 1999-04-20 2000-10-26 Philogen S.R.L. A tenascin-c isoform as a marker for neoplasias

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PANCOOK J D ET AL: "In vitro affinity maturation of human IgM antibodies reactive with tumor-associated antigens.", HYBRIDOMA AND HYBRIDOMICS. 2001, vol. 20, no. 5-6, 2001, pages 383 - 396, XP002348142, ISSN: 1536-8599 *
PRAT M ET AL: "CAR-3 A MONOCLONAL ANTIBODY-DEFINED ANTIGEN EXPRESSED ON HUMAN CARCINOMAS", CANCER RESEARCH, vol. 45, no. 11 PART 2, 1985, pages 5799 - 5807, XP009055057, ISSN: 0008-5472 *
See also references of WO03044036A1 *
WU H ET AL: "STEPWISE IN VITRO AFFINITY MATURATION OF VITAXIN, AN ALPHAVBETA3-SPECIFIC HUMANIZED MAB", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 95, no. 11, 26 May 1998 (1998-05-26), pages 6037 - 6042, XP000918969, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2003044036A1 (en) 2003-05-30
MXPA04004658A (es) 2004-08-13
CA2467020A1 (en) 2003-05-30
EP1446416A1 (de) 2004-08-18
AU2002365978A1 (en) 2003-06-10
CN1615315A (zh) 2005-05-11
BR0214288A (pt) 2004-11-09
JP2005517388A (ja) 2005-06-16

Similar Documents

Publication Publication Date Title
EP1432444A4 (de) Anti-a-beta-antikörper
HK1074206A1 (en) Anti-trail-r antibodies
IL166244A0 (en) Super humanized antibodies
IL156030A0 (en) Humanized antibodies
AU1174702A (en) Humanized anti-lt-beta-r antibodies
EP1391464A4 (de) Monoklonaler anti-cd-40-antikörper
EP1383801A4 (de) Antikörper gegen krebs
HK1153763A1 (en) Anti-her2 antibody variants
HK1153649A1 (zh) 治療性抗 單克隆抗體
AU2003264009A8 (en) Humanized rabbit antibodies
EP1443963A4 (de) Antikörper-targeting-verbindungen
HUP0402333A3 (en) Modified anti-tnf alpha antibody
AU2002365649A8 (en) Anti-dota antibody
GB0126378D0 (en) Antigen
EP1462456A4 (de) Tumorantigene
EP1178829A4 (de) Menschlicher monoklonaler antikörper
IL158184A0 (en) Anti-muc-1 single chain antibodies for tumor targeting
EP1454914A4 (de) Tumorantigen
EP1446416A4 (de) Tumorspezifische monoklonale antikörper
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
EP1403283A4 (de) Tumorantigen
GB0121727D0 (en) Monoclonal antibodies
GB0003359D0 (en) Monoclonal antibodies
GB0008160D0 (en) Monoclonal antibodies
GB0119553D0 (en) Antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040527

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20051018

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080603